A Phase 3 interventional study of TNX-102 SL and Placebo SL Tablets in PTSD, sponsored by Tonix Pharmaceuticals, Inc.. Terminated at 30 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-02-06.
Sponsored by Tonix Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 341 open to participants now, 404 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 259th largest by enrollment of the 1,491 interventional ones that give a count, is one of 94 that started in 2019, is one of 64 in phase 3, and was the 906th registered.
2,687 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.
Browse Stress Disorders, Post-Traumatic studies →341 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–55
Summit Hyperbarics and Wellness · Sites in United States
Ages 18–75
Anthony Vesco · Sites in United States
Ages 8–18
Transcend Therapeutics · Sites in United States
Ages 18+
COMPASS Pathways · Sites in United States, Canada
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 417 Stress Disorders, Post-Traumatic studies recruiting now, 187 (45%) set no upper age limit and 204 (49%) stop at 75 or younger; 63 take children under 18; 89 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,664 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 132 · Phase 2 234 · Phase 3 95 · Phase 4 90
First in 1991; this study’s year is marked. 94 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 69 across 2,201 interventional studies indexed under Stress Disorders, Post-Traumatic.
Median enrollment 65 across the 1,491 interventional studies, 107 across the 165 observational. Of the 1,135 that completed or were terminated, 491 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
98 of 1,664 have an industry lead sponsor. The 10 most frequent:
Tonix Pharmaceuticals, Inc. is the lead sponsor of 34 studies on the registry; 1 is open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 12 (71%) have results posted.
Tonix Pharmaceuticals, Inc. has 7 studies filed under Stress Disorders, Post-Traumatic — fewer than ten, so there is no comparison to draw.
154 of the studies in Stress Disorders, Post-Traumatic with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06117306Phase 3Healing BreakthroughMDMA-assisted Massed Prolonged Exposure for PTSD | 2027-03 |
| NCT04877093Phase 3Wake Forest University Health SciencesRepurposing Low-Dose Clonidine for PTSD in Veterans | 2027-03-31 |
| NCT06273527Phase 3University of California, San DiegoEnhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol (R33) | 2027-06-01 |
| NCT07217795University of Rhode IslandRecovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building | 2026-11 |
| NCT04585685Christal L BadourHealthy Recovery After Trauma Study | 2026-11 |
Add all 154 to your calendar (.ics) → With an account.
Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of TNX-102 SL 5.6 mg (2 x 2.8 mg tablets) - a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
2 x TNX-102 SL, 2.8 mg Tablets taken sublingually each day at bedtime for 12 weeks.
Drug: TNX-102 SL
2 x Placebo Tablets taken sublingually each day at bedtime for 12 weeks.
Drug: Placebo SL Tablets
Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Also known as: Low dose cyclobenzaprine sublingual tablets, Tonmya(R)
Patients will take 2 tablets of randomly assigned study drug sublingually starting on Day 1 for 12 weeks
Also known as: Placebo sublingual tablets, TNX-102 SL Placebo Tablets
Mean Change From Baseline in the Total CAPS-5 Score
The primary efficacy endpoint is the mean change from baseline (Day 1) in the total CAPS-5 score after 12 weeks of treatment. The CAPS-5 is an updated and validated version of a semi-structured interview that has been designed to assess the essential features of PTSD as defined by the DSM-5. The total score ranges from 0 to 80 with higher scores indicating more severe PTSD symptoms.
Time frame: Day 1, Week 12
Clinical Global Impression of Severity (CGI-S)
Change from baseline (Day 1) in CGI-S score at Week 12. CGI-S range from 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients).
Time frame: Day 1, Week 12
Sheehan Disability Scale (SDS)
Change from baseline in Sheehan Disability Scale (SDS) total score after 12 weeks of treatment comparing the 5.6 mg treatment arm to placebo. The SDS is a self-report questionnaire that was designed to assess the participant's view of the degree to which symptoms have disrupted work/school, social life/leisure activities, and family life/home responsibilities during the previous two weeks. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.
Time frame: Day 1, Week 12
Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance
Change from baseline (Day 1) to Week 12 in the PROMIS Sleep Disturbance scale. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
Time frame: Day 1, Week 12
| Milestone | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Started | 93 | 99 |
| Completed | 64 | 59 |
| Not completed | 29 | 40 |
The primary efficacy endpoint is the mean change from baseline (Day 1) in the total CAPS-5 score after 12 weeks of treatment. The CAPS-5 is an updated and validated version of a semi-structured interview that has been designed to assess the essential features of PTSD as defined by the DSM-5. The total score ranges from 0 to 80 with higher scores indicating more severe PTSD symptoms.
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Mean Change From Baseline in the Total CAPS-5 Score | -18.5 ± 1.90 | -20.7 ± 1.97 |
Change from baseline (Day 1) in CGI-S score at Week 12. CGI-S range from 1 (Normal, not ill at all) to 7 (Among the most extremely ill patients).
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Clinical Global Impression of Severity (CGI-S) | -1.5 ± 0.17 | -2.0 ± 0.18 |
Change from baseline in Sheehan Disability Scale (SDS) total score after 12 weeks of treatment comparing the 5.6 mg treatment arm to placebo. The SDS is a self-report questionnaire that was designed to assess the participant's view of the degree to which symptoms have disrupted work/school, social life/leisure activities, and family life/home responsibilities during the previous two weeks. Score ranges from 0 to 30. A score of 0 means the patient is unimpaired, and a score of 30 means the patient is highly impaired.
| units on a scale | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Sheehan Disability Scale (SDS) | -7.6 ± 0.97 | -9.4 ± 1.01 |
Change from baseline (Day 1) to Week 12 in the PROMIS Sleep Disturbance scale. The PROMIS Sleep disturbance short form 8a consists of 8 questions on a 5-point scale (1 to 5) where a higher score indicates a worse outcome. The total score is reported on a range of 8 to 40. Raw scores are converted to T-scores based on US population with score of 50 as average with a standard deviation of 10.
| T-score | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance | -9.4 ± 1.51 | -13.0 ± 1.57 |
Collected over 14 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo SL Tablet | 0/93 (0%) | 2/91 (2.2%) | 17/91 (18.7%) |
| TNX-102 SL Tablet, 5.6 mg | 0/99 (0%) | 0/96 (0%) | 46/96 (47.9%) |
| Event | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Cholecystic AcuteHepatobiliary disorders | 1/91 | 0/96 |
| Anaphylactic reactionImmune system disorders | 1/91 | 0/96 |
| AbcessInfections and infestations | 1/91 | 0/96 |
| Jaw FractureInjury, poisoning and procedural complications | 1/91 | 0/96 |
| Event | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg |
|---|---|---|
| Hypoaesthesia OralGastrointestinal disorders | 1/91 | 28/96 |
| Dry MouthGastrointestinal disorders | 3/91 | 8/96 |
| Paraesthesia OralGastrointestinal disorders | 1/91 | 7/96 |
| NauseaGastrointestinal disorders | 5/91 | 1/96 |
| HeadacheNervous system disorders | 5/91 | 3/96 |
| Tongue DiscomfortGastrointestinal disorders | 0/91 | 5/96 |
| Upper respiratory tract infectionInfections and infestations | 4/91 | 5/96 |
| Age, Continuous(years) | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg | Total |
|---|---|---|---|
| Mean | 37.2 ± 10.67 | 39.8 ± 11.61 | 38.5 ± 11.16 |
| Sex: Female, Male(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg | Total |
|---|---|---|---|
| Female | 74 | 78 | 152 |
| Male | 19 | 21 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 16 | 19 | 35 |
| Not Hispanic or Latino | 77 | 80 | 157 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 0 | 3 | 3 |
| Native Hawaiian or Other Pacific Islander | 5 | 1 | 6 |
| Black or African American | 11 | 15 | 26 |
| White | 71 | 73 | 144 |
| More than one race | 2 | 2 | 4 |
| Unknown or Not Reported | 3 | 4 | 7 |
| Region of Enrollment(participants) | Placebo SL Tablet | TNX-102 SL Tablet, 5.6 mg | Total |
|---|---|---|---|
| United States | 93 | 99 | 192 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2019 to primary completion in Apr 2020, 13 months.
Results were first posted in Feb 2025, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cyclobenzaprine
Stress Disorders, Post-Traumatic →